金正大生态工程集团股份有限公司 2025 年第三季度报告 证券代码：002470 证券简称：金正大 公告编号：2025-044 金正大生态工程集团股份有限公司 □是 否 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个 别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 2,520,238,510.60 | 38.70% | 7,319,201,309.42 | 14.44% ...

Financial Performance - The company's revenue for Q3 2025 reached ¥339,489,688.70, representing an increase of 82.01% compared to the same period last year[4] - Net profit attributable to shareholders was ¥22,431,577.10, up 48.42% year-on-year, while net profit after deducting non-recurring gains and losses was ¥22,353,496.31, an increase of 54.49%[4] - Total operating revenue for the current period reached ¥773,248,117.76, a significant increase from ¥429,435,724.97 in the previous period, representing a growth of approximately 80%[16] - Net profit for the current period was ¥67,916,644.10, slightly down from ¥69,169,035.27, reflecting a decrease of around 1.8%[17] - The company's basic earnings per share decreased to ¥0.37 from ¥0.83, a decline of approximately 55%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,890,474,965.19, a decrease of 0.48% from the end of the previous year[4] - Total assets decreased to ¥2,890,474,965.19 from ¥2,904,440,164.19, a reduction of about 0.5%[15] - Total liabilities decreased to ¥911,844,074.38 from ¥1,005,183,426.82, a decline of approximately 9.3%[15] - The company's accounts payable decreased by 35.38% year-to-date, primarily due to payments made for project costs[8] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥64,952,958.26, down 27.12% compared to the previous year[4] - Operating cash inflow for the current period reached ¥571,501,797.08, a significant increase from ¥385,343,927.96 in the previous period, representing a growth of approximately 48.3%[20] - Net cash flow from operating activities decreased to ¥64,952,958.26 from ¥89,118,726.29, reflecting a decline of about 27.0%[21] - Cash inflow from investment activities totaled ¥1,352,326,992.39, slightly down from ¥1,399,031,682.89, a decrease of approximately 3.3%[21] - The net increase in cash and cash equivalents for the current period was ¥284,041,693.88, up from ¥69,772,841.49, representing a growth of approximately 305.5%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,584[10] - The largest shareholder, Wang Cainan, holds 34.20% of shares, totaling 45,817,994 shares[10] - The number of shares held by the top ten shareholders includes significant stakes from both individual and institutional investors, indicating concentrated ownership[10] Research and Development - The company reported a significant increase in research and development expenses, which rose by 117.53% year-on-year, primarily due to data from the consolidated subsidiary[8] - Research and development expenses increased to ¥42,886,584.64 from ¥19,715,554.97, showing a growth of approximately 117%[16] Other Financial Metrics - The weighted average return on equity was 1.23%, a decrease of 0.15% year-on-year[4] - The company's cash and cash equivalents increased to ¥543,643,919.02 from ¥241,053,545.45, representing a growth of 125.5%[13] - Accounts receivable rose to ¥437,351,067.45 from ¥339,934,731.69, an increase of 28.7%[13] - Inventory decreased to ¥337,030,607.15 from ¥388,408,983.75, a decline of 13.2%[13] - The company reported a total of 79,536,111.11 in trading financial assets, down from 300,417,528.26, a decrease of 73.5%[13] - The company reported a decrease in other comprehensive income, with a net amount of ¥313,128.21 compared to ¥1,747,198.09 in the previous period, a decline of about 82%[18] - The total equity attributable to shareholders increased to ¥1,816,045,437.63 from ¥1,755,514,345.81, reflecting a growth of approximately 3.4%[15] Future Outlook - Future outlook and strategic initiatives will be discussed in subsequent reports, focusing on market expansion and new product development[12] Audit Information - The company did not undergo an audit for the third quarter financial report[22]

烟台亚通精工机械股份有限公司 2025 年第三季度报告 证券代码：603190 证券简称：亚通精工 烟台亚通精工机械股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 454,077,620.35 | 27.12 | 1,28 ...

江苏康为世纪生物科技股份有限公司 2025 年第三季度报告 证券代码：688426 证券简称：康为世纪 江苏康为世纪生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 1 / 13 单位：元 币种：人民币 项目 本报告期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 52,455,562.72 68.47 139,574,234.46 42.01 利润总额 -21,249,963.37 54.96 -81,880,016.30 21.98 归属于上市公司股东的 净 ...

Financial Performance - The company's operating revenue for the third quarter was ¥130,039,526.89, a decrease of 15.87% compared to the same period last year[3]. - Total profit for the quarter was ¥12,494,752.97, down 48.16% year-on-year[3]. - Net profit attributable to shareholders was ¥10,952,688.00, reflecting a decline of 45.66% compared to the previous year[3]. - The basic earnings per share for the quarter was ¥0.08, a decrease of 55.56% year-on-year[3]. - Total operating revenue for the first three quarters of 2025 reached ¥398,180,432.24, a slight increase from ¥390,816,368.30 in the same period of 2024, representing a growth of approximately 0.93%[19]. - The net profit for the first three quarters of 2025 reached ¥58,625,749.54, an increase of 16.5% compared to ¥50,337,922.51 in the same period of 2024[20]. - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.42, slightly up from ¥0.41 in the same period of 2024[20]. Research and Development - Research and development expenses totaled ¥7,784,426.48, accounting for 5.99% of operating revenue, an increase of 1.75 percentage points[4]. - Research and development expenses increased to ¥21,096,099.18 in 2025 from ¥19,834,731.06 in 2024, marking an increase of about 6.4%[19]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥128,296,599.37, a significant increase of 1,268.59% compared to the previous year[3]. - Cash and cash equivalents as of September 30, 2025, amounted to ¥438,226,897.19, up from ¥284,205,896.01 at the end of 2024, representing a growth of approximately 54.3%[14]. - Total assets at the end of the reporting period were ¥1,748,226,296.50, representing a 2.71% increase from the end of the previous year[4]. - Total assets as of September 30, 2025, were ¥1,748,226,296.50, compared to ¥1,702,023,099.33 at the end of 2024, showing an increase of approximately 2.7%[15]. - The company's retained earnings increased to ¥513,013,576.86 in 2025 from ¥465,769,398.40 in 2024, reflecting a growth of approximately 10.1%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,274[9]. - The largest shareholder, Yuan Jianhua, holds 41,072,020 shares, representing 29.26% of total shares[9]. - JET (H.K.) BIOSCIENCE holds 17,547,293 shares, accounting for 12.50% of total shares[9]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[10]. Legal Matters - The company is involved in a lawsuit with Shanghai You Electronic Technology Co., Ltd. regarding a contract dispute, with a claim amount of RMB 18,441,691.80 and a penalty of RMB 1,386,000[11]. - The court ruled that Shanghai You must return RMB 11,256,957.82 to the company and pay a penalty of RMB 922,084.59[11]. - The company is also in a legal dispute with Shenzhen Hesheng Medical Technology Co., Ltd. over a mold procurement contract, with a claim amount of RMB 10,340,829.00 and damages of RMB 644,911[12]. - The court ordered Hesheng Medical to return the claimed amount and compensate for damages, but Hesheng Medical has appealed the decision[12]. - The company has had part of its funds frozen amounting to RMB 11,473,149.78 due to ongoing litigation[13]. - The company is actively managing its legal disputes to mitigate financial impacts and protect shareholder interests[11]. Operating Costs - Total operating costs for the first three quarters of 2025 were ¥340,567,157.86, compared to ¥329,050,630.04 in 2024, indicating an increase of about 3.8%[19]. - The total cash outflow from operating activities in the first three quarters of 2025 was ¥392,674,512.47, a decrease from ¥423,922,874.13 in the same period of 2024[22].

富岭科技股份有限公司 2025 年第三季度报告 证券代码：001356 证券简称：富岭股份 公告编号：2025-042 富岭科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 1 富岭科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 493,534,366.05 | -18.76% | 1,509, ...

翱捷科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 翱捷科技股份有限公司 2025 年第三季度报告 证券代码：688220 证券简称：翱捷科技 | 利润 | | | | | | --- | --- | --- | --- | --- | | 经营活动产生的现金流 | 不适用 | 不适用 | -290,071,728.98 | 不适用 | | 量净额 | | | | | | 基本每股收益（元/股） | -0.20 | 不适用 | -0.81 | 不适用 | | 稀释每股收益（元/股） | -0.20 | 不适用 | -0.81 | 不适用 | | 加权平均净资产收益率 （%） | -1.48 | 不适用 | -5.85 | 不适用 | | 研发投入合计 | 336,196,626.63 | 8.60 | 1,004,647,581.40 | 11.07 | | 研发投入占营业收入的 | 34.22 | 减 少 0.78 个 | 34.88 | 减少0.74个 | | 比例（%） | ...

证券代码：600833 证券简称：第一医药 上海第一医药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 上海第一医药股份有限公司 2025 年第三季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 一、主要财务数据 （一） 主要会计数据和财务指标 1 / 10 单位：元 币种：人民币 项目 本报告期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 年初至报告 期末比上年 同期增减变 动幅度(%) 营业收入 542,480,778.50 14.04 1,539,077,117.96 12.43 利润总额 52,374,952.68 124.02 70,118,313.89 -63.85 归属于上市公司股东的净利润 39,245 ...

Financial Performance - The company's operating revenue for the third quarter was ¥114,539,032.74, a decrease of 6.54% compared to the same period last year[4]. - The total profit for the year-to-date period reached ¥25,365,780.91, with a net profit attributable to shareholders of ¥27,632,247.92[4]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥17,364,632.37 for the third quarter[4]. - Total operating revenue for the first three quarters of 2025 was CNY 350,629,873.70, a decrease of 2.14% compared to CNY 359,402,017.18 in the same period of 2024[20]. - Net profit for the first three quarters of 2025 was CNY 27,627,752.51, a turnaround from a net loss of CNY 28,400,706.00 in the same period of 2024[22]. - The company reported a total profit of CNY 25,365,780.91 for the first three quarters of 2025, compared to a total loss of CNY 22,988,834.03 in the previous year[22]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥60,020,426.83, representing a significant increase of 417.50%[5]. - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $422.92 million, an increase from $406.77 million in the same period of 2024, representing a growth of about 4%[24]. - The net cash flow from operating activities significantly improved to $60.02 million in 2025, compared to $11.60 million in 2024, indicating a substantial increase in operational efficiency[24]. - Total cash outflow for operating activities was approximately $362.90 million in 2025, a decrease from $395.17 million in 2024, indicating better cost management[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,131,853,844.83, reflecting a 1.22% increase from the end of the previous year[5]. - Total current assets increased to ¥418,032,263.40 from ¥366,665,116.02, a growth of approximately 14.0%[15]. - Total liabilities decreased slightly to CNY 513,251,593.45 from CNY 516,587,993.08[20]. - Non-current assets totaled ¥1,713,821,581.43, down from ¥1,739,587,919.89, a decrease of approximately 1.5%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 28,285[12]. - Shanghai Yanghe Industrial Co., Ltd. holds 20.82% of shares, with 78,249,836 shares pledged[12]. - Chen Dekang, a natural person, holds 11.67% of shares, totaling 43,871,004 shares[12]. Earnings Per Share - The basic earnings per share for the third quarter was ¥0.01, unchanged from the previous year[5]. - The diluted earnings per share for the third quarter was also ¥0.01, consistent with the previous year[5]. - Basic earnings per share for the first three quarters of 2025 was CNY 0.07, compared to a loss of CNY 0.08 in the same period of 2024[22]. Cost Management - The company has implemented cost control measures, resulting in a reduction in management expenses compared to the previous year[9]. - Total operating costs decreased significantly to CNY 336,856,292.82 from CNY 401,137,647.70, representing a reduction of approximately 16.06%[21]. - Research and development expenses decreased to CNY 14,861,974.29 from CNY 44,765,811.58, a reduction of approximately 66.8%[21]. Government Subsidies - The company reported a significant increase in government subsidies recognized, amounting to ¥1,583,793.41 for the year-to-date period[7]. Investment Activities - Cash outflow from investment activities totaled approximately $127.50 million in 2025, a decrease from $282.94 million in 2024, reflecting a reduction in capital expenditures[25]. - The net cash flow from investment activities was negative at -$85.68 million in 2025, an improvement from -$188.69 million in 2024, suggesting better investment management[25]. - The company received approximately $40.47 million from other investment-related cash inflows in 2025, a significant increase from $10.09 million in 2024, reflecting improved investment returns[25]. Financial Reporting - The company did not apply new accounting standards for the first time in 2025, maintaining consistency in financial reporting[26].

Financial Performance - The company's operating revenue for the third quarter was ¥332,924,485.39, representing a year-on-year increase of 2.03%[4] - The total profit for the quarter was ¥30,704,135.81, reflecting a growth of 10.97% compared to the same period last year[4] - The net profit attributable to shareholders was ¥26,181,422.31, which is an increase of 6.31% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥27,367,135.43, showing a significant increase of 21.56% compared to the previous year[4] - The company's net profit for the first three quarters of 2025 reached CNY 82,703,612, a slight increase from CNY 82,573,962 in the same period of 2024, representing a growth of 0.16%[22] - Operating profit for the first three quarters of 2025 was CNY 92,638,730, compared to CNY 90,477,420 in 2024, indicating an increase of 2.4%[22] - Total revenue from operating activities for the first three quarters of 2025 was CNY 1,063,985,892.58, up from CNY 1,052,185,145.08 in 2024, reflecting a growth of 1.8%[24] - The total comprehensive income for the first three quarters of 2025 was CNY 84,942,340.77, slightly higher than CNY 84,309,316.98 in 2024, showing an increase of 0.75%[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,119,167,643.39, a rise of 1.30% from the end of the previous year[5] - Total assets as of September 30, 2025, amounted to RMB 2,119,167,643.39, compared to RMB 2,091,907,982.18 at the end of 2024[16] - Total liabilities decreased to RMB 548,824,218.59 from RMB 592,087,705.88 year-over-year[16] - Shareholders' equity increased to RMB 1,570,343,424.80 from RMB 1,499,820,276.30 in the previous year[17] Earnings and Cash Flow - The basic earnings per share for the quarter was ¥0.14, which is a 7.69% increase from the same period last year[5] - The diluted earnings per share also stood at ¥0.14, consistent with the basic earnings per share[5] - The net cash flow from operating activities for the year-to-date was ¥107,838,530.23, reflecting a decrease of 15.58% compared to the previous year[5] - The net cash flow from operating activities for the first three quarters of 2025 was CNY 107,838,530.23, down from CNY 127,733,009.89 in 2024, a decrease of 15.6%[25] - The company reported a net cash outflow from investing activities of CNY -82,491,746.80 for the first three quarters of 2025, an improvement compared to CNY -153,932,228.77 in 2024[26] - The company’s cash and cash equivalents at the end of the period were CNY 181,066,907.59, compared to CNY 169,883,379.66 at the end of the same period in 2024, an increase of 6.9%[26] Costs and Expenses - Total operating costs for the first three quarters of 2025 were RMB 860,327,507.70, down 3.2% from RMB 888,258,221.54 in the previous year[20] - Operating costs included RMB 728,173,562.70 in operating expenses, which decreased from RMB 761,322,317.72 year-over-year[20] - Research and development expenses for the first three quarters of 2025 amounted to CNY 47,382,916.68, compared to CNY 46,222,550.75 in 2024, an increase of 2.5%[22] - The company reported a tax expense of CNY 9,552,364.60 for the first three quarters of 2025, up from CNY 8,729,771.02 in 2024, reflecting an increase of 9.4%[22] - The company reported non-recurring gains and losses totaling -¥1,185,713.12 for the quarter[8] - The company's financial expenses for the first three quarters of 2025 were CNY -1,422,486.75, compared to CNY -738,987.07 in 2024, indicating a worsening of 92.6%[22] Inventory and Cash Equivalents - Cash and cash equivalents as of September 30, 2025, were RMB 197,062,398.71, down from RMB 213,337,444.00 at the end of 2024[14] - Inventory as of September 30, 2025, was RMB 238,757,404.28, slightly up from RMB 235,589,533.35 at the end of 2024[15] Market and Product Development - No significant new product launches or market expansion strategies were mentioned during the earnings call[18]